Jefferies downgrades Mitie to “hold” following Marlowe deal

Jefferies downgraded Mitie Group Plc to "hold" from "buy," citing a shift in strategy after the Marlowe acquisition, which introduces integration risks and alters the investment outlook. The brokerage notes the stock's 30% year-to-date gain and valuation near the top of its historical P/E range limit further re-rating, while also flagging concerns about Marlowe’s business model and Mitie's declining EBITA-to-free cash flow conversion. Jefferies forecasts 7% organic revenue growth for FY26 and FY27, but points to difficult prior-year comparisons, a competitive pricing environment, and muted organic expectations from Marlowe.

Analysis

Jefferies has downgraded Mitie Group Plc (MTO) to "hold" from "buy," primarily due to a strategic shift initiated by the acquisition of Marlowe, which introduces integration risks and alters the company's investment profile away from its prior focus on organic growth and share buybacks. This re-evaluation comes as Mitie's stock has appreciated 30% year-to-date, trading at 11x FY26 earnings per share, near the upper end of its historical 8–12x P/E range, thereby limiting further re-rating potential. The Marlowe transaction, characterized by Jefferies as having mixed financial metrics, suspends Mitie's buyback program and is projected to deliver 0% EPS accretion in FY26, increasing to 9% by FY28 assuming £30 million in cost synergies, while leverage is expected to reach 1.4x net debt to EBITDA in FY26, the ceiling of management's target range. Concerns also extend to Marlowe's roll-up business model and weak free cash flow record, compounded by a decline in Mitie's own EBITA-to-free cash flow conversion from 77% in FY24 to 61% in FY25, attributed to working capital outflows from project growth and extended retail client payment terms. While Jefferies forecasts 7% organic revenue growth for FY26/FY27, this is tempered by difficult prior-year comparisons, competitive pricing, and Marlowe's modest 4% projected organic growth. Furthermore, Mitie's targeted EBITA margin above 5% by FY27 is seen as largely acquisition-driven, with organic margin expansion expected at only 10 basis points and FY26 margins predicted to be flat year-over-year due to a £25 million inflation and National Insurance headwind and the loss of higher-margin contracts. Consequently, Jefferies views the risk-reward profile as more balanced, cutting its price target to 145p.

Key Decisions for Investors

• Investors should consider the increased risk profile stemming from Mitie's strategic pivot towards larger M&A with the Marlowe acquisition, noting the suspension of share buybacks and potential integration challenges.
• Re-assess Mitie's valuation in light of its significant year-to-date share price increase to 11x FY26 P/E, the top of its historical range, and Jefferies' price target of 145p which suggests limited near-term upside.
• Monitor key operational metrics such as EBITA-to-free cash flow conversion, which has fallen to 61%, and organic revenue growth, given pressures from capital projects, payment terms, and lower growth expectations for Marlowe.
• Evaluate the sustainability of future margin improvements, as these are anticipated to be largely driven by acquisition synergies rather than organic expansion, and factor in the expected flat margin performance in FY26 due to cost pressures and contract losses.